CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.

Valuation also favors CVS. While UNH trades at a forward P/E of 12.98X, CVS trades at a more modest 10.31. This valuation gap ...

CVS Health CVS has seen its stock surge by 53.7% in 2025, fueled by a potent combination of strong operational performance ...

A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.